374 related articles for article (PubMed ID: 26183105)
1. Current Status of Five Different Regimens for Empiric First-Line Helicobacter pylori Eradication in Turkey.
Gungor G; Baglıcakoglu M; Kayacetin E; Biyik M; Ucar R; Goktepe H; Ataseven H; Demir A
Digestion; 2015; 92(2):55-9. PubMed ID: 26183105
[TBL] [Abstract][Full Text] [Related]
2. Comparison of sequential and standard triple-drug regimen for Helicobacter pylori eradication: a 14-day, open-label, randomized, prospective, parallel-arm study in adult patients with nonulcer dyspepsia.
Uygun A; Kadayifci A; Yesilova Z; Safali M; Ilgan S; Karaeren N
Clin Ther; 2008 Mar; 30(3):528-34. PubMed ID: 18405790
[TBL] [Abstract][Full Text] [Related]
3. Concomitant therapy achieved the best eradication rate for Helicobacter pylori among various treatment strategies.
Lee HJ; Kim JI; Lee JS; Jun EJ; Oh JH; Cheung DY; Chung WC; Kim BW; Kim SS
World J Gastroenterol; 2015 Jan; 21(1):351-9. PubMed ID: 25574111
[TBL] [Abstract][Full Text] [Related]
4. A Randomized Controlled Trial Shows that both 14-Day Hybrid and Bismuth Quadruple Therapies Cure Most Patients with Helicobacter pylori Infection in Populations with Moderate Antibiotic Resistance.
Tsay FW; Wu DC; Yu HC; Kao SS; Lin KH; Cheng JS; Wang HM; Chen WC; Sun WC; Tsai KW; Hsu PI
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28807915
[TBL] [Abstract][Full Text] [Related]
5. A pilot study evaluating sequential administration of a PPI-amoxicillin followed by a PPI-metronidazole-tetracycline in Turkey.
Sezgin O; Altintaş E; Nayir E; Uçbilek E
Helicobacter; 2007 Dec; 12(6):629-32. PubMed ID: 18001405
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcomes of two-week sequential and concomitant therapies for Helicobacter pylori eradication: a randomized pilot study.
Lim JH; Lee DH; Choi C; Lee ST; Kim N; Jeong SH; Kim JW; Hwang JH; Park YS; Lee SH; Shin CM; Jo HJ; Jang ES; Song Is; Jung HC
Helicobacter; 2013 Jun; 18(3):180-6. PubMed ID: 23305083
[TBL] [Abstract][Full Text] [Related]
7. Comparison of bismuth-containing quadruple and concomitant therapies as a first-line treatment option for Helicobacter pylori.
Kadayifci A; Uygun A; Polat Z; Kantarcioğlu M; Kılcıler G; Başer O; Ozcan A; Emer O
Turk J Gastroenterol; 2012 Feb; 23(1):8-13. PubMed ID: 22505373
[TBL] [Abstract][Full Text] [Related]
8. Randomized comparison of ranitidine bismuth citrate-based triple therapies for Helicobacter pylori.
Laine L; Estrada R; Trujillo M; Emami S
Am J Gastroenterol; 1997 Dec; 92(12):2213-5. PubMed ID: 9399755
[TBL] [Abstract][Full Text] [Related]
9. Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
Liou JM; Fang YJ; Chen CC; Bair MJ; Chang CY; Lee YC; Chen MJ; Chen CC; Tseng CH; Hsu YC; Lee JY; Yang TH; Luo JC; Chang CC; Chen CY; Chen PY; Shun CT; Hsu WF; Hu WH; Chen YN; Sheu BS; Lin JT; Wu JY; El-Omar EM; Wu MS;
Lancet; 2016 Nov; 388(10058):2355-2365. PubMed ID: 27769562
[TBL] [Abstract][Full Text] [Related]
10. Comparison of sequential therapy and amoxicillin/tetracycline containing bismuth quadruple therapy for the first-line eradication of Helicobacter pylori: a prospective, multi-center, randomized clinical trial.
Lee JY; Kim N; Park KS; Kim HJ; Park SM; Baik GH; Shim KN; Oh JH; Choi SC; Kim SE; Kim WH; Park SY; Kim GH; Lee BE; Jo Y; Hong SJ
BMC Gastroenterol; 2016 Jul; 16(1):79. PubMed ID: 27460100
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Helicobacter pylori Eradication Rates of 2-Week Levofloxacin-Containing Triple Therapy, Levofloxacin-Containing Bismuth Quadruple Therapy, and Standard Bismuth Quadruple Therapy as a First-Line Regimen.
Kahramanoğlu Aksoy E; Pirinçci Sapmaz F; Göktaş Z; Uzman M; Nazlıgül Y
Med Princ Pract; 2017; 26(6):523-529. PubMed ID: 29131124
[TBL] [Abstract][Full Text] [Related]
12. Ranitidine bismuth citrate-based triple therapies as a second-line therapy for Helicobacter pylori in Turkish patients.
Köksal AS; Parlak E; Filik L; Yolcu OF; Odemiş B; Ulker A; Saşmaz N; Ozden A; Sahin B
J Gastroenterol Hepatol; 2005 Apr; 20(4):637-42. PubMed ID: 15836716
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic success with bismuth-containing sequential and quadruple regimens in Helicobacter pylori eradication.
Ozturk O; Doganay L; Colak Y; Yilmaz Enc F; Ulasoglu C; Ozdil K; Tuncer I
Arab J Gastroenterol; 2017 Jun; 18(2):62-67. PubMed ID: 28601610
[TBL] [Abstract][Full Text] [Related]
14. Bismuth-based first-line therapy for Helicobacter pylori eradication in type 2 diabetes mellitus patients.
Demir M; Göktürk S; Oztürk NA; Serin E; Yilmaz U
Digestion; 2010; 82(1):47-53. PubMed ID: 20410684
[TBL] [Abstract][Full Text] [Related]
15. Bismuth subsalicylate instead of metronidazole with lansoprazole and clarithromycin for Helicobacter pylori infection: a randomized trial.
Chey WD; Fisher L; Elta GH; Barnett JL; Nostrant T; DelValle J; Hasler WL; Scheiman JM
Am J Gastroenterol; 1997 Sep; 92(9):1483-6. PubMed ID: 9317068
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of quadruple therapy with pantoprazole, bismuth, tetracycline and metronidazole as rescue treatment for Helicobacter pylori infection.
Boixeda D; Bermejo F; Martín-De-Argila C; López-Sanromán A; Defarges V; Hernández-Ranz F; Milicua JM; García-Plaza A
Aliment Pharmacol Ther; 2002 Aug; 16(8):1457-60. PubMed ID: 12182745
[TBL] [Abstract][Full Text] [Related]
17. The impact of bismuth addition to sequential treatment on Helicobacter pylori eradication: A pilot study.
Basyigit S; Kefeli A; Sapmaz F; Yeniova AO; Asilturk Z; Hokkaomeroglu M; Uzman M; Nazligul Y
Bosn J Basic Med Sci; 2015 Oct; 15(4):50-4. PubMed ID: 26614852
[TBL] [Abstract][Full Text] [Related]
18. Comparison of three different second-line quadruple therapies including bismuth subcitrate in Turkish patients with non-ulcer dyspepsia who failed to eradicate Helicobacter pylori with a 14-day standard first-line therapy.
Uygun A; Ozel AM; Yildiz O; Aslan M; Yesilova Z; Erdil A; Bagci S; Gunhan O
J Gastroenterol Hepatol; 2008 Jan; 23(1):42-5. PubMed ID: 17559359
[TBL] [Abstract][Full Text] [Related]
19. The efficacy of bismuth containing quadruple therapy as a first-line treatment option for Helicobacter pylori.
Uygun A; Kadayifci A; Safali M; Ilgan S; Bagci S
J Dig Dis; 2007 Nov; 8(4):211-5. PubMed ID: 17970879
[TBL] [Abstract][Full Text] [Related]
20. Bismuth-based therapies for the first step eradication of Helicobacter pylori.
Sezgin O; Altintaş E; Uçbilek E; Tataroğlu C
Turk J Gastroenterol; 2006 Jun; 17(2):90-3. PubMed ID: 16830288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
